Stockreport

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

Foghorn Therapeutics Inc.  (FHTX) 
PDF • Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of 2024 • FHD-909, a first-in-class BRM select [Read more]